Stockscreener 앱 받기
0.6552
2.67%
-0.018
전일 마감가:
$0.6732
열려 있는:
$0.6877
하루 거래량:
151.57K
Relative Volume:
0.24
시가총액:
$21.00M
수익:
-
순이익/손실:
$-55.92M
주가수익비율:
-0.4647
EPS:
-1.41
순현금흐름:
$-43.07M
1주 성능:
-7.33%
1개월 성능:
-16.02%
6개월 성능:
-83.62%
1년 성능:
-67.24%
1일 변동 폭
$0.6403
$0.6925
1주일 범위
$0.6403
$0.7245
52주 변동 폭
$0.61
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
명칭
Skye Bioscience Inc
전화
(858) 410-0266
주소
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs MOBBW, PSNYW, GOODO, SHMD, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
2.52 | 3.71B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.58 | 414.42M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
19.91 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
6.52 | 377.54M | 52.15M | -21.46M | 0 | -0.4675 |
|
DWLD
Davis Select Worldwide ETF
|
43.90 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2025-08-15 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-09-30 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-09 | 개시 | Craig Hallum | Buy |
| 2024-05-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-04-12 | 개시 | Oppenheimer | Outperform |
모두보기
Skye Bioscience Inc 주식(SKYE)의 최신 뉴스
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice - TipRanks
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency - Investing.com
Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Skye Bioscience (SKYE) after shares stay under $1 minimum - Stock Titan
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy - MSN
Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF) - The Globe and Mail
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pio - GuruFocus
Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral By Investing.com - Investing.com Canada
Citizens reiterates Skye Bioscience stock rating on weight loss data By Investing.com - Investing.com Canada
Skye Bioscience (SKYE) Advances Nimacimab Development with Promi - GuruFocus
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ... By GuruFocus - Investing.com Canada
Skye Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
SKYE: Additive weight loss and durable efficacy drive nimacimab's advancement as a GLP-1 add-on - TradingView
Skye Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SKYE) 2026-03-10 - Seeking Alpha
Earnings call transcript: Skye Bioscience Q4 2025 highlights clinical advancements - Investing.com
Skye Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Skye (SKYE) Reinforces Nimacimab Strategy with Promising Data - GuruFocus
Q4 and full year results reveal momentum, Skye Bioscience, Inc. asserts - Traders Union
Skye Bioscience 2025 10-K: Net loss $(55.9M), Loss per share $(1.41) - TradingView
Skye Bioscience (NASDAQ: SKYE) highlights nimacimab obesity and metabolic pipeline - Stock Titan
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - ChartMill
Skye Bioscience Q4 2025 earnings preview - MSN
A Peek at Skye Bioscience's Future Earnings - Benzinga
Skye confirms phase 2 data on nimacimab for obesity expected later this year - MSN
Growth Value: Will Skye Bioscience Inc benefit from government policyQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Market Recap: Can Skye Bioscience Inc weather a recessionEarnings Growth Summary & Risk Managed Investment Strategies - baoquankhu1.vn
Growth Report: What are the analyst revisions for Skye Bioscience IncIs KNSL stock a good investment in YEARVolume Spike & Low Volatility Stock Suggestions - baoquankhu1.vn
Does Skye Bioscience Inc have a competitive edgeJuly 2025 Catalysts & Low Drawdown Momentum Ideas - baoquankhu1.vn
Smart Money: Can Skye Bioscience Inc beat the S P 5002025 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Risk Report: Whats the outlook for Skye Bioscience Incs sectorJuly 2025 Closing Moves & Expert Curated Trade Ideas - baoquankhu1.vn
Skye Bioscience Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Aug Intraday: Is Skye Bioscience Inc in a bullish channelQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Breakout Zone: Will Skye Bioscience Inc outperform the market in YEARIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - Sahm
Why Did Skye Bioscience Stock Plummet A Whopping 60% Today? - Stocktwits
Skye Bioscience schedules March 2026 earnings release with Q4 and full-year results - Traders Union
Skye Bioscience to Release 2025 Financial Results and Business Update on March 10, 2026 - geneonline.com
Skye Bioscience : Corporate Presentation View Presentation ( 260221 Skye Corporate Presentation ) - marketscreener.com
Skye Bioscience Stock Quote, Share Price, News and Analysis - Longbridge
SKYE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Can Skye Bioscience Inc weather a recessionWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Volume Summary: Should I hold or sell FATBP nowJuly 2025 Drop Watch & Risk Managed Investment Signals - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
SKYE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SKYE Earnings History & Surprises | EPS & Revenue Results | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience says Kaitlyn Arsenault to step down as CFO effective Feb 20 - marketscreener.com
CFO exits Skye Bioscience (SKYE) with $450k severance; CEO takes accounting duties - Stock Titan
2026-02-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-02-17 | Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Skye Bioscience Inc (SKYE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):